Feb 12, 2020
Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and other serious diseases, announced that it signed an exclusive license agreement with the University of Pittsburgh for a diabetes gene therapy that may have the potential to cure Type 1 and Type 2 diabetes, which together currently affects approximately 30.3 million people in the U.S or 9 percent of the U.S. population.
The diabetes gene therapy, which was developed by lead researcher and Harvard graduate, Dr. George Gittes, at the Rangos Research Center at UPMC Children’s Hospital of Pittsburgh, works by reprogramming beta cells in the pancreas to restore their function, thereby replenishing levels of insulin. The novel infusion process uses an endoscope and an adeno-associated virus (AAV) vector to deliver Pdx1 and MafA genes to the pancreas. The proteins these genes express transform alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body’s immune system.
The diabetes gene therapy has been tested in vivo in mice and nonhuman primates. In studies of diabetic mice, the gene therapy approach restored normal blood glucose levels for an extended period of time, typically around four months. According to Dr. Gittes, the duration of restored blood glucose levels in mice could translate to decades in humans. Following preclinical studies, Dr. Gittes and his team plan to begin a Phase I clinical trial in diabetic patients, which could be the first-ever gene therapy tested in humans for diabetes.
“One of the biggest advantages of this gene therapy is that it could eliminate the need for insulin replacement therapy for diabetic patients,” said Dr. Gittes. “Lifting this huge burden for the millions of patients who must continuously monitor blood glucose levels and inject insulin daily would be a breakthrough in modern medicine. This therapy has the potential to truly disrupt the diabetes market.”
Genprex will add this exciting technology to its research and development pipeline, diversifying its portfolio and expanding its clinical development programs. The company will continue its focus on developing its immunogene therapies for cancer, including Oncoprex™ immunogene therapy, its lead drug candidate for non-small cell lung cancer, in parallel with the development of the new diabetes gene therapy.
“We are excited to announce the licensing agreement with The University of Pittsburgh, and we look forward to working with Dr. Gittes and his team to develop this groundbreaking treatment for diabetes,” said Rodney Varner, Genprex’s Chairman and Chief Executive Officer. “At Genprex, we have always put patient needs first, focusing on ways to bring new treatment options to patient populations who have large unmet medical needs. We believe this diabetes gene therapy may potentially become a new treatment option for the millions of diabetes patients who now must take insulin replacement therapy, and it may be effective for patients who do not benefit sufficiently from that therapy. Even more moving, the diabetes gene therapy could hold the potential to provide long term effectiveness, or even be a cure, for diabetes patients.”
Genprex plans to pursue potential partnerships for the development of this therapy globally and in the U.S.
According to the American Diabetes Association, more than 30 million Americans have diabetes, and approximately 1.5 million Americans are diagnosed with diabetes every year. Diabetes patients have a continuous burden of checking and monitoring their blood glucose levels and injecting insulin on a daily basis. Without effective management of diabetes, patients are at risk of stroke, hyperglycemia, cardiovascular disease, diabetic ketoacidosis, and extremity amputation. Diabetes is the seventh leading cause of death in the U.S.
About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and other serious diseases. Genprex’s technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and other serious diseases that currently have limited treatment options. Genprex works with world-class institutions and collaborators to in-license and develops drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches for patients with cancer and other serious diseases. The company’s lead product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC), uses the company’s unique, proprietary platform which delivers cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. In January 2020, the FDA granted Fast Track Designation for Oncoprex in combination with AstraZeneca’s Tagrisso® for the treatment of NSCLC.
Published: Jan 19, 2021
Published: Jan 12, 2021
Published: Jan 7, 2021
Published: Dec 17, 2020
Published: Nov 28, 2020
Published: Nov 7, 2020
Published: Oct 22, 2020
Published: Oct 21, 2020
Published: Oct 20, 2020
Published: Oct 19, 2020
Published: Oct 7, 2020
Published: Oct 4, 2020
Published: Sep 30, 2020
Published: Sep 23, 2020
Published: Sep 18, 2020
Published: Sep 11, 2020
Published: Sep 8, 2020
Published: Sep 2, 2020
Published: Aug 27, 2020
Published: Aug 23, 2020
Published: Aug 23, 2020
Published: Aug 23, 2020
Published: Aug 23, 2020
Published: Aug 23, 2020
Published: Aug 23, 2020
Published: Aug 23, 2020
Published: Aug 23, 2020
Published: Aug 23, 2020
Published: Aug 21, 2020
Published: Aug 12, 2020
Published: Aug 6, 2020
Published: Aug 6, 2020
Published: Aug 4, 2020
Published: Aug 3, 2020
Published: Jul 27, 2020
Published: Jul 24, 2020
Published: Jul 9, 2020
Published: Jul 9, 2020
Published: Jul 5, 2020
Published: Jul 3, 2020
Published: Jul 3, 2020
Published: Jul 2, 2020
Published: Jul 2, 2020
Published: Jul 2, 2020
Published: Jul 2, 2020
Published: Jul 1, 2020
Published: Jul 1, 2020
Published: Jul 1, 2020
Published: Jun 28, 2020
Published: Jun 27, 2020
Published: Jun 23, 2020
Published: Jun 16, 2020
Published: Jun 13, 2020
Published: Jun 11, 2020
Published: Jun 11, 2020
Published: Jun 11, 2020
Published: Jun 9, 2020
Published: Jun 4, 2020
Published: May 28, 2020
Published: May 21, 2020
Published: May 21, 2020
Published: May 20, 2020
Published: May 20, 2020
Published: May 18, 2020
Published: May 17, 2020
Published: May 17, 2020
Published: May 17, 2020
Published: May 14, 2020
Published: May 14, 2020
Published: May 13, 2020
Published: May 12, 2020
Published: May 12, 2020
Published: May 11, 2020
Published: May 6, 2020
Published: May 5, 2020
Published: May 4, 2020
Published: May 3, 2020
Published: Apr 30, 2020
Published: Apr 30, 2020
Published: Apr 30, 2020
Published: Apr 29, 2020
Published: Apr 29, 2020
Published: Apr 28, 2020
Published: Apr 27, 2020
Published: Apr 26, 2020
Published: Apr 24, 2020
Published: Apr 22, 2020
Published: Apr 21, 2020
Published: Apr 21, 2020
Published: Apr 19, 2020
Published: Apr 19, 2020
Published: Apr 17, 2020
Published: Apr 17, 2020
Published: Apr 16, 2020
Published: Apr 16, 2020
Published: Apr 15, 2020
Published: Apr 13, 2020
Published: Apr 12, 2020
Published: Apr 8, 2020
Published: Apr 6, 2020
Published: Apr 5, 2020
Published: Apr 4, 2020
Published: Apr 4, 2020
Published: Apr 4, 2020
Published: Apr 4, 2020
Published: Apr 3, 2020
Published: Apr 3, 2020
Published: Apr 2, 2020
Published: Mar 31, 2020
Published: Mar 31, 2020
Published: Mar 31, 2020
Published: Mar 31, 2020
Published: Mar 31, 2020
Published: Mar 30, 2020
Published: Mar 27, 2020
Published: Mar 27, 2020
Published: Mar 26, 2020
Published: Mar 24, 2020
Published: Mar 23, 2020
Published: Mar 20, 2020
Published: Mar 18, 2020
Published: Mar 18, 2020
Published: Mar 18, 2020
Published: Mar 18, 2020
Published: Mar 16, 2020
Published: Mar 16, 2020
Published: Mar 16, 2020
Published: Mar 14, 2020
Published: Mar 13, 2020
Published: Mar 12, 2020
Published: Mar 12, 2020
Published: Mar 10, 2020
Published: Mar 9, 2020
Published: Mar 9, 2020
Published: Mar 6, 2020
Published: Mar 6, 2020
Published: Mar 6, 2020
Published: Mar 5, 2020
Published: Mar 4, 2020
Published: Mar 3, 2020
Published: Mar 3, 2020
Published: Mar 3, 2020
Published: Mar 2, 2020
Published: Mar 2, 2020
Published: Mar 2, 2020
Published: Mar 1, 2020
Published: Feb 28, 2020
Published: Feb 28, 2020
Published: Feb 28, 2020
Published: Feb 26, 2020
Published: Feb 24, 2020
Published: Feb 23, 2020
Published: Feb 23, 2020
Published: Feb 23, 2020
Published: Feb 23, 2020
Published: Feb 18, 2020
Published: Feb 18, 2020
Published: Feb 18, 2020
Published: Feb 18, 2020
Published: Feb 14, 2020
Published: Feb 14, 2020
Published: Feb 12, 2020
Published: Feb 12, 2020
Published: Feb 11, 2020
Published: Feb 11, 2020
Published: Feb 10, 2020
Published: Feb 9, 2020
Published: Feb 8, 2020
Published: Feb 1, 2020
Published: Jan 31, 2020
Published: Jan 31, 2020
Published: Jan 31, 2020
Published: Jan 31, 2020
Published: Jan 31, 2020
Published: Jan 29, 2020
Published: Jan 26, 2020
Published: Jan 21, 2020
Published: Jan 21, 2020
Published: Jan 19, 2020
Published: Jan 17, 2020
Published: Jan 16, 2020
Published: Jan 14, 2020
Published: Jan 13, 2020
Published: Jan 13, 2020
Published: Jan 13, 2020
Published: Jan 10, 2020
Published: Jan 9, 2020
Published: Jan 9, 2020
Published: Jan 8, 2020
Published: Jan 7, 2020
Published: Jan 6, 2020
Published: Jan 4, 2020
Published: Jan 3, 2020
Published: Jan 3, 2020
Published: Jan 3, 2020
Published: Dec 30, 2019
Published: Dec 25, 2019
Published: Dec 21, 2019
Published: Dec 21, 2019
Published: Dec 21, 2019
Published: Dec 21, 2019
Published: Dec 18, 2019
Published: Dec 18, 2019
Published: Dec 9, 2019
Published: Dec 4, 2019
Published: Dec 4, 2019
Published: Dec 3, 2019
Published: Dec 3, 2019
Published: Dec 2, 2019
Published: Nov 28, 2019
Published: Nov 28, 2019
Published: Nov 28, 2019
Published: Nov 26, 2019
Published: Nov 26, 2019
Published: Nov 25, 2019
Published: Nov 19, 2019
Published: Nov 18, 2019
Published: Nov 16, 2019
Published: Nov 16, 2019
Published: Nov 14, 2019
Published: Nov 12, 2019
Published: Nov 11, 2019
Published: Nov 11, 2019
Published: Nov 8, 2019
Published: Nov 8, 2019
Published: Nov 7, 2019
Published: Nov 7, 2019
Published: Nov 7, 2019
Published: Nov 6, 2019
Published: Oct 23, 2019
Published: Oct 23, 2019
Published: Oct 20, 2019
Published: Oct 20, 2019
Published: Oct 20, 2019
Published: Oct 20, 2019
Published: Oct 19, 2019
Published: Oct 12, 2019
Published: Oct 12, 2019
Published: Oct 12, 2019
Published: Oct 12, 2019
Published: Oct 12, 2019
Published: Oct 12, 2019
Published: Oct 12, 2019
Published: Oct 12, 2019
Published: Oct 12, 2019
Published: Oct 12, 2019
Published: Oct 12, 2019
Published: Oct 12, 2019
Published: Oct 11, 2019
Published: Oct 11, 2019
Published: Oct 11, 2019
Published: Oct 11, 2019
Published: Oct 10, 2019
Published: Oct 10, 2019
Published: Oct 10, 2019
Published: Oct 10, 2019
Published: Oct 10, 2019
Published: Oct 6, 2019
Published: Oct 6, 2019
Published: Oct 5, 2019
Published: Oct 4, 2019
Published: Oct 4, 2019
Published: Oct 3, 2019
Published: Oct 2, 2019
Published: Oct 2, 2019
Published: Oct 2, 2019
Published: Oct 2, 2019
Published: Oct 1, 2019
Published: Oct 1, 2019
Published: Oct 1, 2019
Published: Oct 1, 2019
Published: Sep 29, 2019
Published: Sep 29, 2019
Published: Sep 28, 2019
Published: Sep 28, 2019
Published: Sep 19, 2019
Published: Sep 16, 2019
Published: Sep 16, 2019
Published: Sep 16, 2019
Published: Sep 16, 2019
Published: Sep 15, 2019
Published: Sep 15, 2019
Published: Sep 15, 2019
Published: Sep 14, 2019
Published: Sep 14, 2019
Published: Sep 14, 2019
Published: Sep 13, 2019
Published: Sep 12, 2019
Published: Sep 6, 2019
Published: Sep 5, 2019
Published: Sep 3, 2019
Published: Sep 3, 2019
Published: Sep 3, 2019
Published: Aug 30, 2019
Published: Aug 30, 2019
Published: Aug 29, 2019
Published: Aug 29, 2019
Published: Aug 28, 2019
Published: Aug 23, 2019
Published: Aug 23, 2019
Published: Aug 23, 2019
Published: Aug 23, 2019
Published: Aug 22, 2019
Published: Aug 22, 2019
Published: Aug 21, 2019
Published: Aug 15, 2019
Published: Aug 15, 2019
Published: Aug 15, 2019
Published: Aug 15, 2019
Published: Aug 15, 2019
Published: Aug 14, 2019
Published: Aug 14, 2019
Published: Aug 14, 2019
Published: Aug 11, 2019
Published: Aug 11, 2019
Published: Aug 8, 2019
Published: Aug 1, 2019
Published: Jul 25, 2019
Published: Jul 25, 2019
Published: Jul 25, 2019
Published: Jul 24, 2019
Published: Jul 21, 2019
Published: Jul 21, 2019
Published: Jul 21, 2019
Published: Jul 17, 2019
Published: Jul 16, 2019
Published: Jul 16, 2019
Published: Jul 15, 2019
Published: Jul 8, 2019
Published: Jul 5, 2019
Published: Jul 5, 2019
Published: Jul 4, 2019
Published: Jul 2, 2019
Published: Jul 1, 2019
Published: Jun 30, 2019
Published: Jun 29, 2019
Published: Jun 29, 2019
Published: Jun 19, 2019
Published: Jun 15, 2019
Published: Jun 13, 2019
Published: Jun 11, 2019
Published: Jun 9, 2019
Published: May 30, 2019
Published: May 29, 2019
Published: May 22, 2019
Published: May 5, 2019
Published: May 5, 2019
Published: Apr 25, 2019
Published: Apr 21, 2019
Published: Apr 19, 2019
Published: Apr 19, 2019
Published: Apr 19, 2019
Published: Apr 19, 2019
Published: Apr 19, 2019
Published: Apr 19, 2019
Published: Mar 28, 2019
Published: Mar 16, 2019
Published: Mar 16, 2019
Published: Mar 6, 2019
Published: Feb 25, 2019
Published: Feb 24, 2019
Published: Feb 7, 2019
Published: Feb 2, 2019
Published: Jan 24, 2019
Published: Dec 29, 2018
Published: Dec 29, 2018
Published: Dec 9, 2018
Published: Nov 7, 2018
Published: Oct 5, 2018
Published: Sep 1, 2018
Published: Aug 15, 2018
Published: Jun 12, 2018
Published: Jun 11, 2018
Published: Apr 20, 2018
Published: Mar 31, 2018
Published: Mar 16, 2018
Published: Mar 11, 2018
Published: Feb 18, 2018
Published: Feb 7, 2018
Published: Jan 4, 2018